Covidien (NYSE:COV) and Vida Diagnostics inked a deal for distribution of Vida’s Apollo pulmonary imaging system.
The move is aimed at complimenting Mansfield, Mass.-based Covidien’s pulmonary portfolio, including its i-Logic lung navigation system.
"We are committed to improving patient outcomes. The combination of our technologies results in a powerful, minimally invasive, more informative imaging solution for areas of the lung not accessible by traditional bronchoscopy and for patients who cannot tolerate more invasive procedures," Covidien interventional lung solutions vice president Michael Minette said in prepared remarks. "This collaboration brings together 2 companies dedicated to the early detection, evaluation and treatment of pulmonary disease."
"Our partnership with Covidien is an opportunity to transform the management of patients with lung disease to an objective, evidence-based approach leading to more precise diagnoses and targeted therapies," added Vida Dx president & CEO Susan Wood. "We are thrilled to be collaborating with the leaders in minimally invasive techniques to bring new diagnostic and therapeutic planning opportunities for patients with lung disease."